BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) went up by 0.50% from its latest closing price compared to the recent 1-year high of $6.29. The company’s stock price has collected 6.68% of gains in the last five trading sessions.
Is It Worth Investing in BioCryst Pharmaceuticals, Inc. (NASDAQ :BCRX) Right Now?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) scored a price-to-earnings ratio above its average ratio, recording 17.97 x from its present earnings ratio. Plus, the 36-month beta value for BCRX is at 2.62. Opinions of the stock are interesting as 6 analysts out of 9 who provided ratings for BioCryst Pharmaceuticals, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $8.50, which is -$3.99 below the current price. BCRX currently public float of 161.13M and currently shorts hold a 20.82% ratio of that float. Today, the average trading volume of BCRX was 6.88M shares.
BCRX’s Market Performance
BCRX stocks went up by 6.68% for the week, with a monthly drop of -11.53% and a quarterly performance of -2.92%, while its annual performance rate touched 41.49%. The volatility ratio for the week stands at 5.05% while the volatility levels for the past 30 days are set at 6.26% for BioCryst Pharmaceuticals, Inc.. The simple moving average for the period of the last 20 days is 1.07% for BCRX stocks with a simple moving average of 10.45% for the last 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with BTIG Research repeating the rating for BCRX by listing it as a “Neutral.” The predicted price for BCRX in the upcoming period, according to BTIG Research is $10 based on the research report published on June 17th of the current year 2020.
Barclays, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $7. The rating they have provided for BCRX stocks is “Overweight” according to the report published on May 5th, 2020.
BofA/Merrill gave a rating of “ Buy” to BCRX, setting the target price at $4 in the report published on November 15th of the previous year.
BCRX Trading at -8.02% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.53% of loss for the given period.
Volatility was left at 6.26%, however, over the last 30 days, the volatility rate increased by 5.05%, as shares sank -9.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.52% lower at present.
During the last 5 trading sessions, BCRX rose by +6.68%, which changed the moving average for the period of 200-days by +44.57% in comparison to the 20-day moving average, which settled at $3.93. In addition, BioCryst Pharmaceuticals, Inc. saw 15.65% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BCRX starting from Doyle Anthony, who bought 54,000 shares at the price of $4.08 back on Aug 11. After this action, Doyle Anthony now owns 54,000 shares of BioCryst Pharmaceuticals, Inc., valued at $220,320 using the latest closing price.
Stonehouse Jon P, the President & CEO of BioCryst Pharmaceuticals, Inc., bought 50,000 shares at $1.45 during a trade that took place back on Nov 18, which means that Stonehouse Jon P is holding 778,086 shares at $72,500 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -203.66 for the present operating margin
- +91.60 for the gross margin
The net margin for BioCryst Pharmaceuticals, Inc. stands at -222.99. The total capital return value is set at -85.02, while invested capital returns managed to touch -135.90. Equity return is now at value -603.60, with -75.50 for asset returns.
Based on BioCryst Pharmaceuticals, Inc. (BCRX), the company’s capital structure generated 221.30 points at debt to equity in total, while total debt to capital is 68.88. Total debt to assets is 48.30, with long-term debt to equity ratio resting at -8.36. Finally, the long-term debt to capital ratio is 116.84.
When we switch over and look at the enterprise to sales, we see a ratio of 7.08, with the company’s debt to enterprise value settled at 0.24. The receivables turnover for the company is 3.69 and the total asset turnover is 0.30. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.78.